Glenmark Pharmaceuticals Ltd Launches Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules® – India's First Nebulized Triple Therapy for COPD

This innovative therapy combines three effective COPD medications—Glycopyrronium, Formoterol, and Budesonide—in a single nebulized formulation. By integrating bronchodilators and corticosteroids in one treatment, the therapy enhances bronchodilation, reduces the risk of severe attacks, and eliminates the burden of multiple inhalers. Designed specifically for the Indian population, where over 55 million people suffer from COPD, this therapy addresses significant challenges in patient adherence and disease management. Glenmark continues its commitment to respiratory care, following previous innovations such as India’s first digital inhaler and dry powder formulations.

Key highlights:

Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules® nebulized triple therapy.

First nebulized triple therapy globally combining Glycopyrronium, Formoterol, and Budesonide.

Improves lung function, reduces severe COPD attacks risk, and enhances patient compliance.

Addresses COPD’s high disease burden in India affecting over 55 million individuals.

Developed with exclusive clinical research focused on the Indian population.

Offers a simplified treatment regimen, replacing multiple inhalers with one therapy.

Strengthens Glenmark’s leadership in respiratory innovation and patient-centric care.

Important milestone in improving management of chronic respiratory diseases in India.

This launch represents a significant advancement for COPD patients, promising better outcomes and quality of life.

Sources: NSE India, Business Upturn, Glenmark Pharmaceuticals Ltd.​